Literature DB >> 3557190

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.

B Myers, D N Evans, J Rhodes, B K Evans, B R Hughes, M G Lee, A Richens, D Richards.   

Abstract

In six healthy subjects serum concentrations of 5 amino salicylic acid (5ASA) and acetyl 5ASA were measured for up to 24 hours, and urinary excretion over 48 hours. After an intravenous injection of 3.26 mmol 5ASA serum concentrations fell rapidly with a distribution half-life of 17 +/- 2 min and an elimination half-life of 42 +/- 5 min. After 45 minutes acetyl 5ASA became the dominant compound and after seven hours serum concentrations of both components were almost unrecordable. Orally ingested 5ASA in three preparations to ensure its release in the stomach, small intestine and ileocaecal region respectively gave lower serum concentrations and urinary excretion than those obtained after an intravenous infusion. Bioavailabilities which ranged from 19% for ileocaecal release to 75% for release in the upper gastrointestinal tract, were calculated from areas under the serum concentration curves. Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3557190      PMCID: PMC1432976          DOI: 10.1136/gut.28.2.196

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  6 in total

1.  Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.

Authors:  M J Dew; R E Ryder; N Evans; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

2.  5-Aminosalicylic acid for the treatment of inflammatory bowel disease.

Authors:  M J Dew; B K Evans; J Rhodes
Journal:  Gastroenterology       Date:  1984-08       Impact factor: 22.682

3.  Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.

Authors:  K A Hansson
Journal:  Acta Pharm Suec       Date:  1973-05

4.  Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.

Authors:  M J Dew; P Ebden; N S Kidwai; G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

5.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

Authors:  O Haagen Nielsen; S Bondesen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

6.  An experiment to determine the active therapeutic moiety of sulphasalazine.

Authors:  A K Azad Khan; J Piris; S C Truelove
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321

  6 in total
  31 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 2.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Authors:  Yongjun Wang; Claire E Parker; Tania Bhanji; Brian G Feagan; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-04-21

Review 3.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

Review 4.  Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.

Authors:  S G Nugent; D Kumar; D S Rampton; D F Evans
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

5.  Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors:  N Mahmud; D G Weir; D Kelleher
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

6.  Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.

Authors:  N Mahmud; M A Kamm; J L Dupas; D P Jewell; C A O'Morain; D G Weir; D Kelleher
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

7.  Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration.

Authors:  F N Hussain; R A Ajjan; M Moustafa; N W Weir; S A Riley
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

8.  Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children.

Authors:  L A Christensen; J Fallingborg; B A Jacobsen; K Abildgaard; H H Rasmussen; S N Rasmussen; S H Hansen
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

9.  Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.

Authors:  Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Hidetaka Sasaki; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

10.  Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.

Authors:  Hiroaki Ito; Mitsuo Iida; Takayuki Matsumoto; Yasuo Suzuki; Yoshiyuki Aida; Toyomitsu Yoshida; Yuichi Takano; Toshifumi Hibi
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.